|
Objective: The specific antigen-antibody reaction the principle screening the Houttuynia injection of sensitization immunogenicity ingredients, do preliminary exploration to find the original the Houttuynia injection of sensitization. Methods: Houttuynia injection sensitized guinea pigs after immune serum ELISA detection of serum total immunoglobulin E levels, salting-out method and column chromatography purification and separation of serum immunoglobulin E, according to the antigen-antibody specificity The combination of theory, immunoglobulin E after capturing the the Houttuynia injection raw ingredients and metabolites detected by GC-MS of their differences, which filter out the allergens immunogenicity ingredients. Results: 22 Houttuynia injection screened sensitization the immunogenicity original ingredients and 20 kinds of allergens immunogenicity metabolites. Sensitized immunogenicity original composition were as follows: myristic acid, 7,9 - di-tert-butyl-1 - oxygen spiro (4,5) decyl -6,9 - dienes -2,8 - dione, (1a , 2β, 5a) - (/ -) -5 - methyl-2 - (1 - methylethyl) - cyclohexanol, 2,6,10 - trimethyl-1 - pentadecanoic, heptadecanoic, 2 6,10,14 - methyl - pentadecanoic, n-dodecanoic acid, tetradecanoic, 4 - methyl-1 - (1 - methylethyl)-3 - cyclohexen-1 - ol, 2, 6,10,14 - 4 - methyl - hexadecane, β-myrcene, 2 - (hexadecyloxy) - ethanol, 3 - hexyl dihydro-2 (3H) - furanone, 2 - methyl- - hexadecane, 6,6 - dimethyl-2 - methyl - (1S) - bicyclo [3.1.1] heptane, nonadecanoic stearate -2 - hydroxyethyl methacrylate, Titanium borneol acrylate, methyl-n-nonyl ketone, n-decanoic acid, a, a, 4 - trimethyl-3 - cyclohexen-1 - methanol, 3,7 - dimethyl-1,6 - octadiene -3 - ol; sensitized immunogenicity metabolites were as follows: 4 - isopropyl-1 ,3 - cyclohexanedione, 1 - isopropyl -7 - methyl-9 ,10 - phenanthrenequinone, 5beta, 6beta-ring oxo--17 - oxo-6a-pentyl-4 - demethyl-3 ,5 - cleft androstan-3 - methyl 2 - hexyl-1 - decanol, 7 - methyl - 18 alkoxy, A oxyacetic acid -4 - tridecyl, 3 - ring hexyl dodecyloxy, 2 - (1H-purin--6 - S)-N-[(tetrahydro-2 - furyl) methyl] - B amide, 2 - (hydroxymethyl) - inosine, HEXACONTANE, (-) - (6S, 7R) -6,7 - epoxy - trans - tricyclo [7.3.0.0 (2,6)] dodecane, 3 - ethenyl -3,7,7 - trimethyl -6,10,10 b-three hydroxy-5 - [(3 - isobutoxy amino -3 - oxopropanoyl) oxy] - perhydro - naphthyl and [2,1-b] pyran -1 - one, 1R, 3 - anti - dimethoxy - 2 - methyl cyclohexane, 4,8 - dimethyl-heptadecane, 30 dodecane , 1 - ethyl-4 - (4 - piperidinyl) - piperazine, 4 - oxime methylene-2 ??,2,5,5 - tetramethyl-3 - imidazol-1 - one, 5,8 - tridecane-dione, 8,11 - octadecanedicarboxylic acid methyl ester, 3 - (2,2,3,3 - tetramethylxylylene cyclopropylsulfoximide methyl) -4 - methyl - hexanoic acid. Conclusion: This initial screening the Houttuynia injection-sensitized the immunogenicity original components and metabolites to provide a basis for the study of its clinical allergic reaction mechanisms and exclude sensitization causes of Houttuynia injection, which is expected to resume its clinical use.
|